Pneumagen
Company Details
Status: Private
Employees: 1-10
Location:
St. Andrews, United Kingdom
Type:
sample
Technology:
sample
sample
About: Pneumagen is a clinical-stage biotech company developing Neumifil, a broad-spectrum antiviral, as an intranasal drug for the prophylaxis of a wide range of viral respiratory tract infections (RTIs).
Neumifil is a novel, engineered multivalent Carbohydrate Binding Module (mCBM), which is being developed for the prevention and treatment of Influenza Virus, Respiratory Syncytial Virus, Human Rhinovirus, and Coronavirus infections including SARS-CoV-2 virus.
Neumifil acts by binding directly to sialic aid on host cells and preventing the entry of the viral pathogens into the host. Neumifil was generated using Pneumagen’s proprietary GlycoTarge™ technology that identifies novel mCBMs for further development.
In addition to Neumifil, Pneumagen is harnessing its GlycoTarge™ platform to develop a pipeline of additional therapies targeting other infectious diseases.
Pneumagen was established in 2016 as a spin-out from the University of St Andrews in Scotland giving Pneumagen access to world-class scientific expertise and capabilities in viral RTI’s specifically related to glycobiology.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Pneumagen | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.